

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Senniger, Powers, Leavitt & Roedel

Attorneys at Law

Patents, Trademarks, Copyrights,
Technology Law, Antitrust, Litigation*Patricia K. Fitzsimmons*
*pfitzsimmons@senniger.com*One Metropolitan Square, 16th Floor
Saint Louis, Missouri 63102Telephone: 314-231-5400
Facsimile: 314-231-4342www.senniger.com

March 3, 2003

VIA FACSIMILE NO. (703) 746-3107Examiner Russell Travers
United States Patent and Trademark Office
Washington, D.C. 20231

Re: U.S. App. Ser. No. 09/023,401, filed February 12, 1998
entitled USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-
GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING
HEPATITIS VIRUS INFECTIONS
Our File PHA 6067

Dear Examiner Travers:

* Further to your February 27, 2003, voice mail message to
John K. Roedel, Jr., enclosed is a copy of the claims pending in
copending App. Ser. No. 09/249,220 (Attorney Ref. No. PHA 6109).

If you require any further assistance, please contact me.

Sincerely,



Patricia K. Fitzsimmons, Reg. No. 52,894


*Enclosure

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 1 of 102

What Is Claimed Is:

1. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an anti-hepatitis virus effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

2. The method of claim 1, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

3. The method of claim 2, wherein R is nonyl.

4. The method of claim 1, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 2 of 102

5. The method of claim 4, wherein R is nonyl.

6. The method of claim 5, wherein said alkanoyl is butanoyl.

7. The method of claim 1, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrates;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 3 of 102

N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 4 of 102

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 5 of 102

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutryate;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.


8. The method of claim 1, wherein said pharmaceutically acceptable salt is selected from the group consisting of

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 6 of 102

acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

9. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral composition comprising an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₁ to C₂₀, branched chain alkyl having a chain length of C₁ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 7 of 102

10. The method of claim 9, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

11. The method of claim 10, wherein R is nonyl.

12. The method of claim 9, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

13. The method of claim 12, wherein R is nonyl.

14. The method of claim 13, wherein said alkanoyl is butanoyl.

15. The method of claim 9, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 8 of 102

N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 9 of 102

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 10 of 102

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutryate;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;


U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 11 of 102

N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.

16. The method of claim 9, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

17. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral composition consisting essentially of an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 12 of 102

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₁ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

18. The method of claim 17, wherein R is straight chain alkyl having a chain length of C₁ to C₂₀, and W, X, Y, and Z are each hydrogen.

19. The method of claim 18, wherein R is nonyl.

20. The method of claim 17, wherein R is straight chain alkyl having a chain length of C₁ to C₂₀, and W, X, Y, and Z are each alkanoyl.

21. The method of claim 20, wherein R is nonyl.

22. The method of claim 21, wherein said alkanoyl is butanoyl.

23. The method of claim 17, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 13 of 102

N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 14 of 102

N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 15 of 102

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrates;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 16 of 102

N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.


24. The method of claim 17, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

25. A method for treating a hepatitis virus infection in a mammal, consisting essentially of administering to said mammal an antiviral effective amount of at least one *N*-substituted-1,5-

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 17 of 102

dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

26. The method of claim 25, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

27. The method of claim 26, wherein R is nonyl.

28. The method of claim 25, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

29. The method of claim 28, wherein R is nonyl.

30. The method of claim 29, wherein said alkanoyl is butanoyl.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 18 of 102

31. The method of claim 25, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrates;

N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrates;

N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrates;

N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrates;

N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 19 of 102

N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 20 of 102

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 21 of 102

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutryate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;

N-(3-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;

N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.


32. The method of claim 25, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 22 of 102

ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

33. A method for treating a hepatitis virus infection in a mammal, consisting essentially of administering to said mammal an antiviral effective amount of an antiviral compound consisting essentially of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

34. The method of claim 33, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

35. The method of claim 34, wherein R is nonyl.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 23 of 102

36. The method of claim 33, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

37. The method of claim 36, wherein R is nonyl.

38. The method of claim 37, wherein said alkanoyl is butanoyl.

39. The method of claim 33, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrates;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 24 of 102

N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 25 of 102

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 26 of 102

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrates;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetates;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetates;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and


N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 27 of 102

40. The method of claim 33, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

41. A method for treating a hepatitis virus infection in a mammal, consisting essentially of administering to said mammal a first amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₁ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 28 of 102

a second amount of an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, an immunomodulator, an immunostimulant, and mixtures thereof,

wherein said first and second amounts of said compounds together comprise an anti-hepatitis virus effective amount of said compounds.

42. The method of claim 41, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

42. The method of claim 42, wherein R is nonyl.

43. The method of claim 41, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

44. The method of claim 43, wherein R is nonyl.

45. The method of claim 44, wherein said alkanoyl is butanoyl.

46. The method of claim 41, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 29 of 102

N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 30 of 102

N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 31 of 102

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrates;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 32 of 102

N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

47. The method of claim 41, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

(+)-*cis*-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;
(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
(-)-*cis*-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);
(-)-2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 33 of 102

2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
2',3'-dideoxy-3'-fluorothymidine (FddThd);
2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
2',3'-dideoxy-beta-L-5-thiacytidine;
2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
9-(1,3-dihydroxy-2-propoxymethyl)guanine;
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
2-amino-1,9-[(2-hydroxymethyl-1-(
(hydroxymethyl)ethoxy)methyl]-6H-purin-6-one (gancyclovir);
2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate
(famciclovir);
2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-
one (acyclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine,
diacetate (famciclovir);
3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-
dideoxyribose;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 34 of 102

dideoxy-inosine (ddI);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodo-
uracil (FIAU);
stavudine;
9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate
(Ara-A);
9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate
monohydrate (Ara-AMP);
2-deoxy-3'-thia-5-fluorocytidine;
2',3'-dideoxy-guanine; and
2',3'-dideoxy-guanosine.


48. The method of claim 41, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates or a pharmaceutically acceptable salt thereof, and mixtures thereof; and

wherein said nucleoside or nucleotide antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

49. A method for treating a hepatitis B virus infection in a mammal, comprising administering to said mammal from about 0.1 mg/kg/day to about 100 mg/kg/day of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 35 of 102



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

from about 0.1 mg/person/day to about 500 mg/person/day of a compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, and a mixture thereof.

50. The method of claim 49, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

51. The method of claim 50, wherein R is nonyl.

52. The method of claim 49, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

53. The method of claim 52, wherein R is nonyl.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 36 of 102

54. The method of claim 53, wherein said alkanoyl is butanoyl.

55. The method of claim 49, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrates;

N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,

tetrabutyrates;

N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 37 of 102

N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 38 of 102

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 39 of 102

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrates;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.

56. The method of claim 49, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 40 of 102

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;
(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
(-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);
(-)-2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
2',3'-dideoxy-3'-fluorothymidine (FddThd);
2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
2',3'-dideoxy-beta-L-5-thiacytidine;
2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
9-(1,3-dihydroxy-2-propoxymethyl)guanine;
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy)methyl]-6H-purin-6-one (gancyclovir);
2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandiol diacetate (famciclovir);

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 41 of 102

2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);
3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
dideoxy-inosine (ddI);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil (FIAU);
stavudine;
9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);
9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate monohydrate (Ara-AMP);
2-deoxy-3'-thia-5-fluorocytidine;
2',3'-dideoxy-guanine; and
2',3'-dideoxy-guanosine.

57. The method of claim 49, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003


Page 42 of 102

consisting of *N*-(*n*-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(*n*-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates or a pharmaceutically acceptable salt thereof, and mixtures thereof; and

wherein said nucleoside or nucleotide antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

58. A method for treating a hepatitis B virus infection in a human patient, comprising administering to said human patient from about 0.1 mg/kg/day to about 100 mg/kg/day of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound selected from the group consisting *N*-(*n*-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(*n*-nonyl-)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates or a pharmaceutically acceptable salt thereof, and mixtures thereof, and from about 0.1 mg/person/day to about 500 mg/person/day of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

59. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



(I)

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 43 of 102

substantially exclusive of the administration of an antiviral composition comprising a nucleoside, a nucleotide, an immunomodulator, or an immunostimulant,

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

60. The method of claim 59, further comprising administering said at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

61. The method of claim 59, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

62. The method of claim 61, wherein R is nonyl.

63. The method of claim 59, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

64. The method of claim 63, wherein R is nonyl.

65. The method of claim 64, wherein said alkanoyl is butanoyl.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 44 of 102

66. The method of claim 59, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 45 of 102

N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 46 of 102

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 47 of 102

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrates;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.


67. The method of claim 59, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 48 of 102

ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

68. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



substantially exclusive of the administration of antiviral compounds other than compounds of Formula I,

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₁ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl.

69. The method of claim 68, further comprising administering said at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 49 of 102

70. The method of claim 68, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

71. The method of claim 70, wherein R is nonyl.

72. The method of claim 68, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

73. The method of claim 72, wherein R is nonyl.

74. The method of claim 73, wherein said alkanoyl is butanoyl.

75. The method of claim 68, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 50 of 102

N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 51 of 102

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 52 of 102

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrates;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetates;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 53 of 102


N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;

N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

76. The method of claim 68, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

77. A pharmaceutical composition, comprising an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₁ to C₂₀, branched chain

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 54 of 102

alkyl having a chain length of C_3 to C_{20} in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a pharmaceutically acceptable carrier, excipient, or diluent.

78. The pharmaceutical composition of claim 77, wherein R is straight chain alkyl having a chain length of C_7 to C_{20} , and W, X, Y, and Z are each hydrogen.

79. The pharmaceutical composition of claim 78, wherein R is nonyl.

80. The pharmaceutical composition of claim 77, wherein R is straight chain alkyl having a chain length of C_7 to C_{20} , and W, X, Y, and Z are each alkanoyl.

81. The pharmaceutical composition of claim 80, wherein R is nonyl.

82. The pharmaceutical composition of claim 81, wherein said alkanoyl is butanoyl.

83. The pharmaceutical composition of claim 77, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

- N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
- N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 55 of 102

N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 56 of 102

N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 57 of 102

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 58 of 102


N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;
N-(7-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.

84. The pharmaceutical composition of claim 77, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

85. A pharmaceutical composition, consisting essentially of an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 59 of 102



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C_7 to C_{20} , branched chain alkyl having a chain length of C_3 to C_{20} in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a pharmaceutically acceptable carrier, diluent, or excipient.

86. The pharmaceutical composition of claim 85, wherein R is straight chain alkyl having a chain length of C_7 to C_{20} , and W, X, Y, and Z are each hydrogen.

87. The pharmaceutical composition of claim 86, wherein R is nonyl.

88. The pharmaceutical composition of claim 85, wherein R is straight chain alkyl having a chain length of C_7 to C_{20} , and W, X, Y, and Z are each alkanoyl.

89. The pharmaceutical composition of claim 88, wherein R is nonyl.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 60 of 102

90. The pharmaceutical composition of claim 89, wherein said alkanoyl is butanoyl.

91. The pharmaceutical composition of claim 85, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 61 of 102

N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 62 of 102

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 63 of 102

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.


92. (once amended) The pharmaceutical composition of claim 85, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate,

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 64 of 102

glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

93. A pharmaceutical composition, comprising an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



substantially free of a nucleoside, nucleotide, immunomodulator, or immunostimulant,

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a pharmaceutically acceptable, carrier, diluent, or excipient.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 65 of 102

94. The pharmaceutical composition of claim 93, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

95. The pharmaceutical composition of claim 94, wherein R is nonyl.

96. The pharmaceutical composition of claim 93, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

97. The pharmaceutical composition of claim 96, wherein R is nonyl.

98. The pharmaceutical composition of claim 97, wherein said alkanoyl is butanoyl.

99. The pharmaceutical composition of claim 93, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 66 of 102

N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 67 of 102

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 68 of 102

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrates;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;


U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 69 of 102

N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;
N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and
N-(7,10,13-trioxa-*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.

100. The pharmaceutical composition of claim 93, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

101. A pharmaceutical composition, comprising an antiviral effective amount of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



substantially free of antiviral compounds other than compounds of Formula I,

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 70 of 102

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a pharmaceutically acceptable, carrier, diluent, or excipient.

102. The pharmaceutical composition of claim 101, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

103. The pharmaceutical composition of claim 102, wherein R is nonyl.

104. The pharmaceutical composition of claim 101, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

105. The pharmaceutical composition of claim 104, wherein R is nonyl.

106. The pharmaceutical composition of claim 105, wherein said alkanoyl is butanoyl.

107. The pharmaceutical composition of claim 101, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N- (n-heptyl) -1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 71 of 102

N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 72 of 102

N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 73 of 102

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 74 of 102

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and


N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

108. The pharmaceutical composition of claim 101, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 75 of 102

109. A composition, comprising at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

an antiviral compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral compound, an immunomodulator, an immunostimulant, and mixtures thereof.

110. The composition of claim 109, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

111. The composition of claim 110, wherein R is nonyl.

112. The composition of claim 109, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

113. The composition of claim 112, wherein R is nonyl.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 76 of 102

114. The composition of claim 113, wherein said alkanoyl is butanoyl.

115. The composition of claim 109, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 77 of 102

N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 78 of 102

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 79 of 102

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrates;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetates;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetates;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.

116. The composition of claim 109, wherein said nucleoside
or nucleotide antiviral compound is selected from the group
consisting of:

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-
yl]cytosine;

(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 80 of 102

(-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);
(-)2',3', dideoxy-3'-thiacytidine [(-)-SddC];
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);
1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
2',3'-dideoxy-3'-fluorothymidine (FddThd);
2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
2',3'-dideoxy-beta-L-5-thiacytidine;
2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
9-(1,3-dihydroxy-2-propoxymethyl)guanine;
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy)methyl]-6H-purin-6-one (gancyclovir);
2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);
2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 81 of 102

9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine,
diacetate (famciclovir);
3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (Cl-ddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-
dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
dideoxy-inosine (ddI);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodo-
uracil (FIAU);
stavudine;
9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate
(Ara-A);
9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate
monohydrate (Ara-AMP);
2-deoxy-3'-thia-5-fluorocytidine;
2',3'-dideoxy-guanine; and
2',3'-dideoxy-guanosine.

117. The composition of claim 109, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates or a

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003


Page 82 of 102

pharmaceutically acceptable salt thereof, and mixtures thereof;
and

wherein said nucleoside or nucleotide antiviral compound is
(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

118. A pharmaceutical composition, comprising:

a first amount of at least one N-substituted-1,5-dideoxy-
1,5-imino-D-glucitol compound of Formula I or a pharmaceutically
acceptable salt thereof:



(I)

wherein R is selected from the group consisting of straight
chain alkyl having a chain length of C₇ to C₂₀, branched chain
alkyl having a chain length of C₃ to C₂₀ in the main chain,
alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from
the group consisting of hydrogen, alkanoyl, aroyl, and
trifluoroalkanoyl;

a second amount of an antiviral compound selected from the
group consisting of a nucleoside antiviral compound, a nucleotide
antiviral compound, an immunomodulator, and immunostimulant, and
mixtures thereof; and

a pharmaceutically acceptable carrier, diluent, or
excipient,

wherein said first and second amounts of said compounds
together comprise an antiviral effective amount of said
compounds.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 83 of 102

119. The pharmaceutical composition of claim 118, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

120. The pharmaceutical composition of claim 119, wherein R is nonyl.

121. The pharmaceutical composition of claim 118, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

122. The pharmaceutical composition of claim 121, wherein R is nonyl.

123. The pharmaceutical composition of claim 122, wherein said alkanoyl is butanoyl.

124. The pharmaceutical composition of claim 118, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 84 of 102

N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 85 of 102

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 86 of 102

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrates;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetates;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 87 of 102

N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;

N-(3-oxa-*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol.

125. The pharmaceutical composition of claim 118, wherein said nucleoside or nucleotide antiviral compound is selected from the group consisting of:

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine;

(-)-2'-deoxy-3'-thiacytidine-5'-triphosphate (3TC);

(-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-yl]cytosine (FTC);

(-)-2',3', dideoxy-3'-thiacytidine [(-)-SddC];

1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine (FIAC);

1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FIACTP);

1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil (FMAU);

1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;

2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);

2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);

2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);

2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);

2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);

2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);

2',3'-dideoxy-3'-fluorothymidine (FddThd);

2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);

2',3'-dideoxy-beta-L-5-thiacytidine;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 88 of 102

2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
9-(1,3-dihydroxy-2-propoxymethyl)guanine;
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy)methyl]-6H-purin-6-one (gancyclovir);
2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);
2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);
3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (Cl-ddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;
dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
dideoxy-inosine (ddI);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil (FIAU);
stavudine;
9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate (Ara-A);

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 89 of 102

9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate monohydrate (Ara-AMP);

2-deoxy-3'-thia-5-fluorocytidine;

2',3'-dideoxy-guanine; and


2',3'-dideoxy-guanosine.

126. The pharmaceutical composition of claim 118, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates or a pharmaceutically acceptable salt thereof, and mixtures thereof; and

wherein said nucleoside or nucleotide antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

127. A pharmaceutical composition for treating a hepatitis B virus infection in a mammal, comprising:

from about 0.1 mg to about 100 mg of at least one *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:



(I)

wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 90 of 102

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl;

from about 0.1 mg to about 500 mg of a compound selected from the group consisting of a nucleoside antiviral compound, a nucleotide antiviral, and mixtures thereof; and

a pharmaceutically acceptable carrier, diluent, or excipient.

128. The pharmaceutical composition of claim 127, wherein R is straight chain alkyl having a chain length of C₁ to C₂₀, and W, X, Y, and Z are each hydrogen.

129. The pharmaceutical composition of claim 128, wherein R is nonyl.

130. The pharmaceutical composition of claim 127, wherein R is straight chain alkyl having a chain length of C₁ to C₂₀, and W, X, Y, and Z are each alkanoyl.

131. The pharmaceutical composition of claim 130, wherein R is nonyl.

132. The pharmaceutical composition of claim 131, wherein said alkanoyl is butanoyl.

133. The pharmaceutical composition of claim 127, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 91 of 102

N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(*n*-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;
N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 92 of 102

N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrate;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 93 of 102

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 94 of 102

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetate;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.

134. The pharmaceutical composition of claim 127, wherein
said nucleoside or nucleotide antiviral compound is selected from
the group consisting of:

(+)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-
yl]cytosine;

(-)-2'-deoxy-3'-thiacytidine-5'-triphosphate (3TC);

(-)-cis-5-fluoro-1-[2-(hydroxy-methyl)-[1,3-oxathiolan-5-
yl]cytosine (FTC);

(-)-2',3', dideoxy-3'-thiacytidine [(-)-SddC];

1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
iodocytosine (FIAC);

1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
iodocytosine triphosphate (FIACTP);

1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-
methyluracil (FMAU);

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 95 of 102

1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide;
2',3'-dideoxy-3'-fluoro-5-methyl-dexocytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-dexocytidine (AddMeCyt);
2',3'-dideoxy-3'-fluoro-5-methyl-cytidine (FddMeCyt);
2',3'-dideoxy-3'-chloro-5-methyl-cytidine (ClddMeCyt);
2',3'-dideoxy-3'-amino-5-methyl-cytidine (AddMeCyt);
2',3'-dideoxy-3'-fluorothymidine (FddThd);
2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC);
2',3'-dideoxy-beta-L-5-thiacytidine;
2',3'-dideoxy-beta-L-5-cytidine (beta-L-ddC);
9-(1,3-dihydroxy-2-propoxymethyl)guanine;
2'-deoxy-3'-thia-5-fluorocytosine;
3'-amino-5-methyl-dexocytidine (AddMeCyt);
2-amino-1,9-[(2-hydroxymethyl-1-(hydroxymethyl)ethoxy)methyl]-6H-purin-6-one (gancyclovir);
2-[2-(2-amino-9H-purin-9y)ethyl]-1,3-propandil diacetate (famciclovir);
2-amino-1,9-dihydro-9-[(2-hydroxy-ethoxy)methyl]6H-purin-6-one (acyclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)guanine (penciclovir);
9-(4-hydroxy-3-hydroxymethyl-but-1-yl)-6-deoxy-guanine, diacetate (famciclovir);
3'-azido-3'-deoxythymidine (AZT);
3'-chloro-5-methyl-dexocytidine (ClddMeCyt);
9-(2-phosphonyl-methoxyethyl)-2',6'-diaminopurine-2',3'-dideoxyriboside;
9-(2-phosphonylmethoxyethyl)adenine (PMEA);
acyclovir triphosphate (ACVTP);
D-carbocyclic-2'-deoxyguanosine (CdG);
dideoxy-cytidine;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 96 of 102

dideoxy-cytosine (ddC);
dideoxy-guanine (ddG);
dideoxy-inosine (ddI);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate;
fluoro-arabinofuranosyl-iodouracil;
1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodo-
uracil (FIAU);
stavudine;
9-beta-D-arabinofuranosyl-9H-purine-6-amine monohydrate
(Ara-A);
9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate
monohydrate (Ara-AMP);
2-deoxy-3'-thia-5-fluorocytidine;
2',3'-dideoxy-guanine; and
2',3'-dideoxy-guanosine.

135. The pharmaceutical composition of claim 127, wherein said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a pharmaceutically acceptable salt thereof, *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates or a pharmaceutically acceptable salt thereof, and mixtures thereof; and

wherein said nucleoside or nucleotide antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC).

136. A pharmaceutical composition for treating a hepatitis B virus infection in a human patient, comprising:

from about 0.1 mg to about 100 mg of an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound selected from the group consisting of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol or a

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003


Page 97 of 102

pharmaceutically acceptable salt thereof, *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates or a pharmaceutically acceptable salt thereof, and mixtures thereof;

from about 0.1 mg to about 500 mg of (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate; and

a pharmaceutically acceptable carrier, diluent, or excipient.

137. A salt, comprising an *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:



wherein R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₂₀, branched chain alkyl having a chain length of C₃ to C₂₀ in the main chain, alkoxyalkyl, arylalkyl, and cycloalkylalkyl, and

wherein W, X, Y and Z are each independently selected from the group consisting of hydrogen, alkanoyl, aroyl, and trifluoroalkanoyl; and

a compound selected from the group consisting of a nucleoside having an acidic moiety and a nucleotide.

138. The salt of claim 137, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each hydrogen.

139. The salt of claim 138, wherein R is nonyl.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 98 of 102

140. The salt of claim 137, wherein R is straight chain alkyl having a chain length of C₇ to C₂₀, and W, X, Y, and Z are each alkanoyl.

141. The salt of claim 140, wherein R is nonyl.

142. The salt of claim 141, wherein said alkanoyl is butanoyl.

143. The salt of claim 137, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of:

N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(n-heptyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(n-octyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 99 of 102

N-(*n*-undecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-dodecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-tridecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-tetradecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-pentadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-hexadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-heptadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-octadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-nonadecyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(*n*-eicosyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutryate;

N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol;

U.S. App. Ser. No. 09/249,220

Page 100 of 102

Claims pending as of February 27, 2003

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol;
N-(2-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(4-ethylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(5-methylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(3-propylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(1-pentylpentylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(1-butylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(7-methyloctyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(8-methylnonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(9-methyldecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;
N-(10-methylundecyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrates;

U.S. App. Ser. No. 09/249,220

Page 101 of 102

Claims pending as of February 27, 2003

N-(6-cyclohexylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(4-cyclohexylbutyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(2-cyclohexylethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-cyclohexylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(1-phenylmethyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-phenylpropyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(3-(4-methyl)-phenylpropyl)-1,5-dideoxy-1,5-imino-D-
glucitol, tetrabutyrates;

N-(6-phenylhexyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetrabutyrates;

N-(7-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetates;

N-(3-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(9-oxa-n-decyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(7-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol,
tetraacetates;

N-(3-oxa-n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol; and

N-(7,10,13-trioxa-n-tetradecyl)-1,5-dideoxy-1,5-imino-D-
glucitol.

U.S. App. Ser. No. 09/249,220
Claims pending as of February 27, 2003

Page 102 of 102

144. The salt of claim 137, wherein said nucleoside having an acidic moiety is selected from the group consisting of compounds of Formula II, III, IV, V, and VI.

145. The salt of claim 137, wherein said nucleotide is selected from the group consisting of compounds of Formula II, III, IV, V, and VI.

146. The salt of claim 145, wherein said nucleotide is selected from the group consisting of:

(-)-2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC);
1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine triphosphate (FICTP);
acyclovir triphosphate (ACVTP);
E-5-(2-bromovinyl)-2'-deoxyuridine triphosphate; and
9-beta-D-arabinofuranosyl-9H-purine-6-amine-5'-monophosphate monohydrate (Ara-AMP).

147. The salt of claim 137, wherein:

said *N*-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutrate; and

said nucleotide is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate.

148. A method, comprising reacting *N*-(*n*-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate under salt-forming conditions.

149. A salt formed by the method of claim 148.